Webinar Preview
Epilepsy is a chronic neurological disorder marked by recurring seizures and frequently accompanied by various comorbidities, including motor deficits, attention deficit hyperactivity disorder (ADHD), anxiety, depression and cognitive impairment.
Despite numerous available therapies, seizures in approximately 30 percent of epilepsy patients are not completely managed by available therapies. This webinar will delve into the urgent need to revamp therapy discovery strategies to better address drug-resistant epilepsy and highlight the importance of tackling the associated comorbidities.
Read more...
Next-generation drug discovery for epilepsy is likely to more comprehensively integrate syndrome-specific models into early-stage development processes. Despite over 30 marketed ASMs, a significant proportion of patients continue to suffer from pharmacoresistant epilepsy. This underscores the critical need to innovate discovery strategies to better address the needs of patients with drug-resistant epilepsy and developmental and epileptic encephalopathies.
Read Less...
Research has shown that kindling-induced epileptogenesis is characterized by significant behavioral and neurological changes. For example, behavioral assessments of kindled mice reveal substantial changes in activity and a decrease in risk assessment behaviors.
By attending this webinar, attendees will be able to gain insights into cutting-edge discovery strategies for drug-resistant epilepsy and the significance of addressing associated comorbidities. They will gain the knowledge to explain the role of syndrome-specific models in the development of innovative treatments for epilepsy. Additionally, they will be able to analyze recent research on kindling-induced epileptogenesis and neuroinflammation and evaluate strategies to enhance preclinical testing and improve translational success in clinical trials.
Register for this webinar today to understand how next-generation drug discovery is being pursued by integrating syndrome-specific models into epilepsy research.
Speakers
Melissa Barker-Haliski, PhD, Associate Professor, University of Washington, Department of Pharmaceutics
Dr. Melissa Barker-Haliski is an Associate Professor in the Department of Pharmaceutics at the University of Washington. She obtained a PhD in Pharmacology and Toxicology from the University of Utah.
She has led the identification and pharmacological characterization of a diversity of novel preclinical models for antiseizure drug discovery, with a particular emphasis on developing strategies to uncover precision medicine therapies. Dr. Barker-Haliski was Co-Chair of the American Epilepsy Society/International League Against Epilepsy’s (ILAE) Pharmacology Common Data Elements Working Group from 2014 to 2018.
Read more...
Her research addresses how chronic seizures in Alzheimer’s disease influence functional and pathological trajectory, representing a new precision medicine opportunity to identify untapped therapeutic targets and disease-modifying strategies for neurological disorders.
Read Less...
Leo Silenieks, Scientific Director, Transpharmation Ltd
Leo Silenieks is a Scientific Director at Transpharmation Ltd Canada. He graduated from the University of Toronto with a Bachelor’s degree in Physiology and Mathematics and completed his Master’s in Neuroscience at the University of Guelph.
His passion for model development and harnessing the power of computer science to support neuroscience has been a driving force in his career. At Transpharmation Ltd, Leo has spearheaded the development of the company’s operant conditioning and epilepsy platforms, maintaining a consistent publication record in these areas.
Read more...
Read Less...
(Moderator) Neil Upton, PhD, Former Chief Scientific Officer, Transpharmation Ltd
Neil Upton is a recently retired Chief Scientific Officer at Transpharmation Ltd with a background in Translational Pharmacology who completed his PhD in Pharmacology from the University of Wales Institution of Science and Technology.
Neil has played a key role in defining development strategies underpinning the progression of novel small molecule and natural product therapeutic approaches into clinical trials in epilepsy patients.
Message PresenterWho Should Attend?
This webinar will appeal to professionals in biotech and pharma companies as well we those with the following job titles:
- Academic and research professionals
- Neuroscientists/Geneticists/Behavioral Scientists
- Pharmacologists
- Veterinary and animal care professionals
What You Will Learn
Attendees will learn about:
- Critically assessing the current challenges in ASM discovery and proposing innovative solutions
- Understanding the significance of genetic and syndrome-specific models in modern epilepsy research
- Recognizing the importance of addressing comorbidities and neuroinflammation in the context of chronic seizure exposure
- Applying learned concepts to enhance the efficacy and translatability of preclinical epilepsy research
Xtalks Partner
Transpharmation Ltd
Transpharmation Ltd is a contract research organisation led by scientists. Recognised by drug developers worldwide for researching and delivering life-changing medicines, science will always remain our passion. We specialise in cross-species and cross-therapeutic areas in translational pharmacology with AAALAC accreditation.
Our breadth of neuroscience expertise means clients are able to benchmark their compounds against clinical gold standards in well validated behavioural and molecular assays and includes PK & non-GLP safety, Pain, Epilepsy, Depression & Anxiety, EEG, Aging, Neurodegenerative Disorders, Biomarkers, Cognitive Disorders and more…
We are committed to on-time data delivery and flexibility whether for gold standard models to innovative customized platforms, our research services deliver the critical pieces of information needed to realize the full potential of your preclinical assets.
You Must Login To Register for this Free Webinar
Already have an account? LOGIN HERE. If you don’t have an account you need to create a free account.
Create Account